15644-80-1

Usage

Uses

Used in Pharmaceutical Industry:
2,8-Dimethyl-4-hydroxyquinoline is used as an intermediate in the synthesis of various pharmaceutical drugs. Its unique chemical structure contributes to the development of new medications, enhancing the therapeutic potential of these compounds.
Used in Rubber and Plastics Industry:
2,8-Dimethyl-4-hydroxyquinoline is used as an antioxidant in the rubber and plastics industry. Its antioxidant properties help to prevent the degradation of these materials, thereby extending their lifespan and improving their performance.
Used in Corrosion Inhibition:
2,8-Dimethyl-4-hydroxyquinoline serves as a corrosion inhibitor, protecting metal surfaces from corrosion and extending the service life of equipment and structures in various industries, including oil and gas, construction, and automotive.
Used in Fuel Industry:
As a stabilizer in fuels, 2,8-Dimethyl-4-hydroxyquinoline helps to prevent the degradation of fuel components, ensuring the stability and performance of fuels over time. This contributes to the efficiency and longevity of fuel storage and usage in transportation and energy sectors.

InChI:InChI=1/C11H11NO/c1-7-4-3-5-9-10(13)6-8(2)12-11(7)9/h3-6H,1-2H3,(H,12,13)

Upstream product

• 33240-19-6 ethyl (Z)-3-(o-tolylamino)but-2-enoate 
• 141-97-9 ethyl acetoacetate 
• 95-53-4 o-toluidine 
• 13562-88-4 2-ethylbutyl 3-oxobutanoate 
• 105-45-3 acetoacetic acid methyl ester 
• 33240-19-6 ethyl 3-[(2-methylphenyl)amino]but-2-enoate 

Downstream Products

• 111947-00-3 (4-hydroxy-2,8-dimethyl-[3]quinolyl)-phenyl ketone 
• 32314-39-9 4-chloro-2,8-dimethylquinoline 
• 34550-29-3 2,8-dimethyl-3-formyl-4-hydroxyquinoline 
• 503552-61-2 4-chloro-3-formyl-8-methyl-2-(2-hydroxy-ethen-1-yl)quinoline 
• 49612-06-8 4-hydrazino-2,8-dimethylquinoline 
• 1049804-72-9 2-methyl-6-(3-methyl-1H-pyrazol-5-yl)aniline 

Relevant academic research and scientific papers

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

N1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors

A series of N1-{4-[(10S)-dihydroartemisinin- 10-oxyl]}phenylmethylene-N2-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain- 2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, 1H NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 μM). The best one of this series was compound 9d (IC50 = 0.15 μM). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.

Synthesis, antimicrobial activities and cytogenetic studies of newer diazepino quinoline derivatives via Vilsmeier-Haack reaction

The study of the Vilsmeier-Haack reagent on 4-hydroxyquinaldines resulted in a new versatile intermediate 4-chloro-3-formyl-2-(2-hydroxy-ethene-1-yl)quinolines, which on further treatment with hydrazine hydrate yielded the desired diazepino quinoline derivatives. All the synthesized diazepino quinoline derivatives are screened for their antibacterial and antifungal activities. Cytogenetic analysis of the samples is also reported.

Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

Vilsmeier-Haack reaction on quinaldines

The study of the Vilsmeier-Haack reaction on 4-hydroxyquinaldines resulted with the preparation of rarely existing 4-chloro-3-formyl-2(vinyl-1-ol)-quinolines.

Quinoline derivatives as antitubercular/antibacterial agents

A number of quinoline derivatives of known antibacterial agents have been prepared and tested against the micro-organisms S. coli, S. paratyphi B, S. aureus and in particular against Mycobacterium tuberculosis H37-Rv. It has not been possibfe to establish correlation between antibacterial and antitubercular activities of these compounds. However, the antitubercular effect at MIC of 5 μg/mL against H37Rv shows that many modified compounds are more inhibitory than the parent agents such as 3-aminophenol, sulphamethoxazole, sulphaphenazole, sulphathiazole and monoacetyldapsone; among these the most effective are those with substituents such as 6-methyl, 6-chloro, 6-ethoxy-, or 8-methoxy functions in quinoline moiety.